Liver cancer trial combines chemo infusion with oil embolization to boost effect
NCT ID NCT06632717
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding a temporary oil-based embolization (lipiodol) to standard chemotherapy infusion through the liver artery can shrink tumors better while keeping the liver healthy. The study enrolls 24 adults with advanced liver cancer that cannot be surgically removed. Participants receive cisplatin and fluorouracil chemotherapy every 3 weeks plus lipiodol embolization on day 3 of each cycle, continuing until the disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cisplatin and fluorouracil chemotherapy plus lipiodol embolization
What this could lead to
If successful, this combination could offer a more effective, liver-friendly treatment option for advanced liver cancer patients who cannot have standard therapies.
What could go wrong
This is a small, early-phase study with only 24 participants, so results may not apply broadly. Chemotherapy and embolization carry risks like liver damage, infection, and toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••